"Brain glutathione levels -- a novel biomarker for mild cognitive impairment and Alzheimer's disease." Biol Psychiatry
DPN: More protocolized care (combining oral/topical + SCS where eligible)
Semaglutide and a similar GLP-1 drug, tirzepatide (Mounjaro/Zepbound), had been on the FDAs shortages list since 2022, as the popularity of the medicines, known as GLP-1 receptor agonists, soared
Clinical trials and real-world data consistently show significant weight loss from treatment with Ozempic, Semaglutide and Tirzepatide: Unfortunately, weight regain is a well-documented phenomenon after discontinuation of treatment: SURMOUNT 4 trial- Weight regain after stopping Tirzepatide after 36 weeks versus continuation of treatment Beyond weight regain, the discontinuation of GLP-1 agonists may reverse cardiometabolic benefits: Ongoing trials (e.g., SELECT and SURPASS-CVOT) aim to clarify whether continued use is necessary for sustained cardiovascular risk reduction
pH-dependent degradation mechanisms Peptides are susceptible to various degradation pathways, many of which are pH-dependent